THALES
8.12.2021 08:02:06 CET | Business Wire | Press release
Gireve, the leading B2B digital platform for electric mobility, and Thales, leader in digital security, have collaborated to provide a simple and secure ´Plug & Charge´ access and billing system. The joint solution, based on the Thales Trusted Key Manager and Gireve’s intermediation platform, improves the driver experience, builds trust in a multi players’ ecosystem and also helps meet the ISO 15118 International standard.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006154/en/
While the EV market rapidly expands, convenient access to charging networks becomes a priority. The current charging network is still very fragmented, often proprietary and not available in enough places. A global standardized and interoperable solution is needed as well as an improved management of the delivery of electricity.
Today each e-Mobility Service Provider (eMSP) offers EV drivers an RFID card to access and start a charging session. Gireve and Thales have partnered to create a harmonized ´Plug & Charge´ solution to simplify the experience and ensure the highest level of security for all EV market players.
Drivers simply plug their electric car into any ISO 15118-compatible charging station, without using a physical card, and the billing is automatically associated to the subscription managed for them. As a result drivers can then freely choose an e-Mobility Service Provider and access a wider number of charging stations; while benefitting from a secure automated charging and digital payment experience.
The solution delivers unique credential certificates to each actor in the system from driver to vehicle and charging station. The system, based on Thales Trusted Key Manager then ensures the secure and instant mutual authentication between these actors. The solution also verifies that the right credentials are securely generated and distributed from the right e-Mobility Provider to the associated vehicle and user. The result – a simpler and more secure EV charging experience.
This mutual authentication and secure credentials management also set the basis of a trusted environment for coming smart grid deployments. As the EV market is expected to boom in the coming years, so does electricity need. Indeed, such increasing needs will require improved and safe energy management and delivery to address power peaks demand.
“ For almost 10 years, Gireve has been a central trusted third party for B2B players in the charging sector. Together with Thales, we are confident our solution addresses key challenges to back up the sustainable success of the EV ecosystem. Our joint efforts are all about facilitating energy access, bringing trust through cybersecurity and boosting drivers’ adoption with improved usage.” Eric Plaquet, CEO at Gireve
“Gireve offered Thales a great opportunity to deploy its field-proven expertise in strong authentication and cybersecurity to the smart charging market. Our partnership supports the sustainable e-mobility sector, by smoothing EV charging access and by creating the trust the sector needs to succeed. Looking forward, our collaboration may unleash further use cases to support smart grid development with more efficient energy management.” Christine Caviglioli, Vice President Automotive at Thales
1
https://www.delta-ee.com/downloads/1-research-downloads/2830-whitepaper-ev-forecasts-84-million-evs-on-european-roads-by-2030.html
2
ISO 15118 is an international standard that outlines the digital communication protocol that an electric vehicle (EV) and charging station should use to recharge the EV’s high-voltage battery.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About GIREVE
Combining Market Place, Transactions Processing, and Data Management technologies, GIREVE is the leading B-to-B digital platform for electric recharging, offering the first coverage in terms of number of charge points in Europe. The company manages 3,800 contracts between 277 players in 32 countries and references more than 220,000 charge points, including 149,000 open to roaming.
For almost 10 years, GIREVE has been a central trusted third party for B-to-B players in the charging sector, handling negotiations and transactions independently, securely, according to transparent rules, and in compliance with regulations.
PLEASE VISIT
Thales Group
Market page
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
